Nurix Operating Income from 2010 to 2024

NRIX Stock

USD 22.11 0.88 4.15%

Nurix Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income will likely drop to about -146.5 M in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Nurix Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2019-02-28

Previous Quarter

-48.5 M

Current Value

-54.6 M

Quarterly Volatility

16.7 M

Covid

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.4 M or Interest Income of 13.4 M, as well as many indicators such as Price To Sales Ratio of 4.8, Dividend Yield of 0.0 or PTB Ratio of 1.59. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.

Check out the analysis of Nurix Therapeutics Correlation against competitors.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Nurix Therapeutics over the last few years. Operating Income is the amount of profit realized from Nurix Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Nurix Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Nurix Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Nurix Operating Income Regression Statistics

	Arithmetic Mean	(60,535,882)
	Coefficient Of Variation	(110.99)
	Mean Deviation	59,289,992
	Median	(9,739,000)
	Standard Deviation	67,190,708
	Sample Variance	4514.6T
	Range	174.1M
	R-Value	(0.86)
	Mean Square Error	1287.5T
	R-Squared	0.74
	Significance	0.000044
	Slope	(12,882,261)
	Total Sum of Squares	63204.3T

Nurix Operating Income History

	2024	-146.5 M
	2023	-139.6 M
	2022	-155.1 M
	2021	-183.9 M
	2020	-117.9 M
	2019	-65 M
	2018	-22.2 M

Other Fundumenentals of Nurix Therapeutics

Non Operating Income Net Other

Nurix Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		0.99	0.99	0.75	-0.58	-0.79	0.93	0.97	0.92	0.82	0.99	0.99	0.98	0.99	0.85	0.98	0.89	-0.78	-0.35
Total Stockholder Equity	0.99		0.98	0.71	-0.64	-0.73	0.89	0.94	0.89	0.75	1.0	0.98	0.95	0.99	0.8	0.95	0.86	-0.73	-0.3
Net Tangible Assets	0.99	0.98		0.8	-0.53	-0.82	0.95	0.99	0.92	0.86	0.98	1.0	0.99	0.99	0.9	0.99	0.89	-0.8	-0.32
Current Deferred Revenue	0.75	0.71	0.8		-0.09	-0.79	0.85	0.84	0.79	0.8	0.71	0.78	0.82	0.73	0.82	0.82	0.79	-0.77	-0.37
Net Debt	-0.58	-0.64	-0.53	-0.09		0.02	-0.28	-0.4	-0.28	-0.15	-0.64	-0.53	-0.44	-0.6	-0.21	-0.44	-0.24	-0.01	-0.13
Retained Earnings	-0.79	-0.73	-0.82	-0.79	0.02		-0.89	-0.89	-0.95	-0.89	-0.73	-0.83	-0.88	-0.79	-0.94	-0.88	-0.8	0.99	0.59
Accounts Payable	0.93	0.89	0.95	0.85	-0.28	-0.89		0.97	0.93	0.95	0.89	0.94	0.97	0.92	0.94	0.97	0.96	-0.88	-0.4
Short Term Investments	0.97	0.94	0.99	0.84	-0.4	-0.89	0.97		0.95	0.89	0.94	0.99	1.0	0.97	0.94	1.0	0.91	-0.88	-0.37
Capital Surpluse	0.92	0.89	0.92	0.79	-0.28	-0.95	0.93	0.95		0.89	0.89	0.94	0.95	0.92	0.92	0.95	0.86	-0.95	-0.61
Total Liab	0.82	0.75	0.86	0.8	-0.15	-0.89	0.95	0.89	0.89		0.75	0.86	0.9	0.82	0.95	0.9	0.85	-0.86	-0.48
Net Invested Capital	0.99	1.0	0.98	0.71	-0.64	-0.73	0.89	0.94	0.89	0.75		0.98	0.95	0.99	0.8	0.95	0.86	-0.73	-0.3
Total Current Assets	0.99	0.98	1.0	0.78	-0.53	-0.83	0.94	0.99	0.94	0.86	0.98		0.99	0.99	0.91	0.99	0.88	-0.82	-0.37
Capital Stock	0.98	0.95	0.99	0.82	-0.44	-0.88	0.97	1.0	0.95	0.9	0.95	0.99		0.98	0.94	1.0	0.89	-0.86	-0.38
Net Working Capital	0.99	0.99	0.99	0.73	-0.6	-0.79	0.92	0.97	0.92	0.82	0.99	0.99	0.98		0.87	0.98	0.85	-0.78	-0.35
Short Term Debt	0.85	0.8	0.9	0.82	-0.21	-0.94	0.94	0.94	0.92	0.95	0.8	0.91	0.94	0.87		0.94	0.81	-0.9	-0.43
Common Stock	0.98	0.95	0.99	0.82	-0.44	-0.88	0.97	1.0	0.95	0.9	0.95	0.99	1.0	0.98	0.94		0.89	-0.86	-0.38
Property Plant Equipment	0.89	0.86	0.89	0.79	-0.24	-0.8	0.96	0.91	0.86	0.85	0.86	0.88	0.89	0.85	0.81	0.89		-0.82	-0.31
Net Receivables	-0.78	-0.73	-0.8	-0.77	-0.01	0.99	-0.88	-0.88	-0.95	-0.86	-0.73	-0.82	-0.86	-0.78	-0.9	-0.86	-0.82		0.6
Deferred Long Term Liab	-0.35	-0.3	-0.32	-0.37	-0.13	0.59	-0.4	-0.37	-0.61	-0.48	-0.3	-0.37	-0.38	-0.35	-0.43	-0.38	-0.31	0.6

Click cells to compare fundamentals

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-139.6 M	-146.5 M
Non Operating Income Net Other	4 M	2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nurix Operating Income from 2010 to 2024

Latest Nurix Therapeutics' Operating Income Growth Pattern

Nurix Operating Income Regression Statistics

Nurix Operating Income History

Other Fundumenentals of Nurix Therapeutics

Nurix Therapeutics Operating Income component correlations

About Nurix Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Nurix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY